News | August 22, 2023
LEO Pharma to acquire Timber Pharmaceuticals
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Rare childhood cancer subtype, Ph+ ALL, is found in 3-4% of pediatric cases and 25% of adult cases
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
Subscribe To Our Newsletter & Stay Updated
